Breast Cancer

JAK2 could potentially cause treatment resistance in TNBC.

JAK2 could potentially cause treatment resistance in TNBC.

Treatment costs climb with advanced-stage breast cancer compared with earlier stages.

Neratinib plus paclitaxel did not improve outcomes in metastatic ERBB2-positive breast cancer.

Mevalonate pathway associated with cell-signaling protein that promotes breast cancer development.

Blue-green algae discovered in Panama carries potent anti-cancer activity.

Pfizer announced Ibrance met its primary endpoint in postmenopausal women with human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer.

Pfizer announced Ibrance met its primary endpoint in postmenopausal women with human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer.

Bisphenol A is found in numerous plastic and resin household products.

Individualized approach allows for creation of widespread models of patient-specific tumors.

Recurrence Score test may help some women with breast cancer be spared of chemotherapy without experiencing disease progression.

Evista is typically given to women after menopause to treat and prevent osteoporosis and reduce the risk of invasive breast cancer.

New treatment approach offers less severe side effects from chemotherapy.

Study finds incidence of post-traumatic stress symptoms in breast cancer patients to be underestimated.

Alcohol can affect estrogen in breast cancer cells and weakens the ability of drugs that halt proliferation.

Advocacy group helps breast cancer patient overcome fear and channel her anger to battle the disease.

Tyverb and Herceptin combination shows significant promise treating HER2 positive breast cancer.

Increased inflammation in obese women is thought to increase the risk of breast cancer.

New analysis provides faster tests and lower costs for women with estrogen positive-receptor (ER-positive) breast cancer.

Nanoparticles acting as cancer drug delivery vehicles show promise in eliminating tumors.

Several chemotherapy agents have been investigated for neoadjuvant use in HER2-positive breast cancer.

The management of individual chemotherapy regimens by pharmacists improves safety by reducing medication errors.

Proposal includes giving insurers the ability to withhold products from formularies if the cost of cancer drugs do not represent good value.

Palbociclib (Ibrance) approved for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Ibrance approved for the treatment of HR+, HER2- advanced or metastatic breast cancer.